ArticleJHEP reports : innovation in hepatology2026
Disease-driven loss of inactive HSD17B13 isoforms enhances enzymatic output in MASH and counters protective rs72613567:TA variant.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsWe investigated whether liver disease alters HSD17B13 isoform expression, identifying selective loss of exon 2-skipped variants and uncovering variant B as a structured, noncoding RNA with silencing potential.
methodsHuman liver samples from lean control (n = 6), metabolic dysfunction-associated steatotic liver (MASL, n = 8), and metabolic dysfunction-associated steatohepatitis (MASH, n = 8) participants were analyzed by isoform-specific reverse-transcription PCR and quantitative PCR. HepG2 cells were transfected with HSD17B13 variant A or B constructs. RNA expression, protein production, RNase sensitivity, and RNA structural conformations (RNAfold) were evaluated. Functional effects were tested under oleic acid-induced lipotoxic stress.
resultsWe observed a selective reduction in exon 2-skipped HSD17B13 isoforms (variants B and G) in both human MASL (∼63% vs. lean control; p <0.01) and MASH (∼93% vs. lean control; p <0.001), independent of rs72613567:TA genotype. Notably, variant B nearly abolished endogenous HSD17B13 expression in HepG2 cells (∼99% reduction; p <0.001) without generating detectable protein. RNase III sensitivity assays and RNAfold modeling revealed stable, duplex-rich RNA structures, supporting a noncoding regulatory role for these isoforms under oleic acid-induced lipotoxic stress.
conclusionsRestoration of exon 2-skipped HSD17B13 isoforms, particularly variant B, may offer a genotype-independent therapeutic strategy for MASH by mimicking protective effects through structured RNA-mediated suppression of enzymatic HSD17B13 activity. IMPACT AND IMPLICATIONS: These findings support a dual mechanism of HSD17B13 regulation in liver disease through genotype-mediated transcript suppression and disease-driven isoform imbalance. Therapeutic re-expression of exon 2-skipped isoforms, particularly variant B, may offer a novel strategy to replicate the protective effect of the TA allele without enzymatic inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.